Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A molecular CT blood pool contrast agent.

David R Vera1, Robert F Mattrey

  • 1Department of Radiology, University of California, San Diego 92103-8756, USA.

Academic Radiology
|July 26, 2002
PubMed
Summary

Researchers developed a new water-soluble contrast agent for CT scans that stays in the bloodstream longer than traditional options. This molecule helps improve the visualization of blood vessels and tumors by remaining in the circulation rather than being quickly absorbed by the liver.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Independent Relevance of Estrogen Receptor and Progesterone Receptor Statuses in DCIS on Risk of Subsequent Ipsilateral and Contralateral Invasive Breast Events in Absence of Endocrine Therapy.

Cancers·2026
Same author

Fluorescence Guidance Reduces Operative Time for Sentinel Lymph Node Biopsy in the Head and Neck.

The Laryngoscope·2026
Same author

Multimodal tilmanocept for preoperative imaging and fluorescence-guided surgery of porcine lateral pelvic sentinel lymph nodes.

Scientific reports·2025
Same author

Using <sup>13</sup>N<sub>2</sub> and PET to track <i>in vivo</i> nitrogen gas kinetics during normobaric conditions.

Frontiers in physiology·2025
Same author

Perfluorohexane Emulsions Induce Macrophage-Stimulating Effects through iNOS Expression.

ACS applied bio materials·2025
Same author

The Functional Characterization of Venous Thromboembolic Disease (FUVID) study: rationale, design, and methods of a prospective, observational, multicenter study to evaluate mechanisms of exercise intolerance and dyspnea following pediatric pulmonary embolism.

Research and practice in thrombosis and haemostasis·2025

Area of Science:

  • Diagnostic imaging within dysprosium-DTPA-dextran research
  • Molecular radiology and contrast agent development

Background:

Current medical imaging lacks contrast agents that remain in the bloodstream for extended periods. Existing particulate options often trigger unwanted immune responses from macrophages. This limitation prevents their widespread adoption in clinical settings. No prior work had resolved the need for a stable, water-soluble macromolecular alternative. Researchers require agents that offer prolonged vascular residence times for better tumor detection. That uncertainty drove the development of new synthetic pathways for contrast enhancement. Prior research has shown that traditional iodine-based agents clear from the blood too rapidly. This gap motivated the creation of a specialized molecule designed to overcome these pharmacokinetic hurdles.

Purpose Of The Study:

The study aimed to synthesize a water-soluble macromolecular agent for improved vascular and tumor imaging. Researchers sought to address the lack of contrast agents with prolonged vascular residence times. Current particulate options fail to reach clinical use because they trigger nonspecific macrophage activation. The team designed a molecule that avoids these immune complications while maintaining high metal density. They focused on creating a stable structure that does not require intermolecular cross-linking. This effort addresses the need for better blood pool enhancement during diagnostic procedures. The authors intended to demonstrate that their synthetic approach produces a viable alternative to existing iodine-based products. This work explores the pharmacokinetic advantages of a high-molecular-weight contrast agent in a rabbit model.

Keywords:
vascular imagingcontrast mediamacromolecular agentstumor detection

Frequently Asked Questions

The agent utilizes a macromolecular structure to achieve prolonged vascular residence. By remaining in the bloodstream rather than exiting into tissues, it provides sustained contrast enhancement. This differs from standard iodine-based agents, which clear from the circulation within minutes.

The researchers synthesized the agent by coupling amino-terminated leashes to dextran PM40. These leashes were then attached to DTPA, which subsequently complexed with dysprosium. This multi-step process ensures high metal loading without cross-linking.

An acidic solution of 0.2 M dysprosium chloride is required for the complexation step. This specific chemical environment allows the DTPA-dextran scaffold to bind the metal ions effectively, ensuring the stability of the final contrast agent.

The dextran PM40 scaffold acts as the carrier for the metal groups. Each molecule supports 95 individual DTPA units, which significantly increases the total molecular weight to over 100,000 g/mol for improved circulation.

Related Experiment Videos

Main Methods:

The review approach involved synthesizing a water-soluble macromolecule using dextran PM40 as the base. Researchers activated hydroxyl units with allylbromine before reacting them with amino ethanethiol. They utilized the mixed anhydride method to couple these leashes to DTPA. Complexation occurred within an acidic environment containing dysprosium chloride. The team evaluated the agent in a rabbit model featuring a VX2 tumor. They acquired transaxial scans through the liver and tumor over a 45-minute duration. A separate healthy rabbit received Optiray-320 for comparative pharmacokinetic analysis. Investigators monitored enhancement levels at specific intervals to determine vascular residence times.

Main Results:

The new agent achieved an 8-minute half-time during the initial 15 minutes of observation. Its concentration remained stable with a nearly zero slope for the remainder of the study. The inferior vena cava stayed brighter than the liver throughout the entire period. Solid tumor regions showed enhancement of 5-10 CT numbers, which highlighted necrotic areas. In contrast, the iodine-based Optiray-320 exhibited half-times of 2.5 and 45 minutes. The standard agent became less dense than the liver within 8 minutes. Each dextran molecule carried 95 metal groups, increasing its weight to 101,537 g/mol. The final product demonstrated high solubility and significant metal loading capacity.

Conclusions:

The synthesized agent remains water-soluble without requiring intermolecular cross-linking. It successfully carries a high payload of metal ions for enhanced imaging. The molecule demonstrates superior blood pool retention compared to conventional iodine-based alternatives. Authors suggest this agent provides stable intravascular dwell times during observation. Imaging results indicate that the compound maintains higher density than liver tissue throughout the study. This contrast enhancement allows for clearer identification of necrotic regions within solid tumors. The findings confirm that the macromolecular design achieves the desired pharmacokinetic profile. Synthesis and implications suggest this approach offers a viable path for future vascular diagnostic applications.

The researchers measured the inferior vena cava enhancement over time. They observed an 8-minute half-time for the new agent, whereas the standard iodine-based Optiray-320 showed much faster clearance, becoming less dense than the liver within 8 minutes.

The authors propose that this macromolecular design offers a solution to the limitations of particulate agents. They suggest that the agent's solubility and retention characteristics make it a promising candidate for vascular and tumor imaging applications.